Total Payments
$8,715
2024 Payments
$1,549
Companies
32
Transactions
416
Medicare Patients
1,893
Medicare Billing
$302,421
Payment Breakdown by Category
Food & Beverage$8,154 (93.6%)
Education$429.34 (4.9%)
Other$131.82 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,154 | 399 | 93.6% |
| Education | $429.34 | 10 | 4.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131.82 | 7 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $2,103 | 107 | $0 (2024) |
| Gilead Sciences, Inc. | $1,902 | 88 | $0 (2024) |
| Merck Sharp & Dohme LLC | $984.34 | 58 | $0 (2024) |
| Janssen Biotech, Inc. | $793.80 | 46 | $0 (2023) |
| Theratechnologies Inc. | $453.31 | 19 | $0 (2024) |
| Melinta Therapeutics, LLC | $396.66 | 14 | $0 (2024) |
| ABBVIE INC. | $356.45 | 13 | $0 (2024) |
| Janssen Products, LP | $327.94 | 4 | $0 (2021) |
| Napo Pharmaceuticals Inc | $300.17 | 16 | $0 (2022) |
| Insmed, Inc. | $192.60 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,549 | 61 | Gilead Sciences, Inc. ($387.31) |
| 2023 | $1,547 | 70 | ViiV Healthcare Company ($478.27) |
| 2022 | $1,553 | 75 | ViiV Healthcare Company ($539.21) |
| 2021 | $1,163 | 55 | Gilead Sciences, Inc. ($309.15) |
| 2020 | $325.97 | 17 | ViiV Healthcare Company ($79.06) |
| 2019 | $741.02 | 39 | Janssen Biotech, Inc. ($169.52) |
| 2018 | $1,201 | 60 | Janssen Biotech, Inc. ($288.56) |
| 2017 | $634.82 | 39 | ViiV Healthcare Company ($146.00) |
All Payment Transactions
416 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: HIV | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.69 | General |
| 12/10/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $29.05 | General |
| Category: HIV | ||||||
| 11/22/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.99 | General |
| 11/12/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $34.68 | General |
| Category: HIV | ||||||
| 11/07/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: HIV | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), ZERBAXA, DIFICID | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/22/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $37.14 | General |
| Category: HIV | ||||||
| 10/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.11 | General |
| 10/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.04 | General |
| 10/08/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: HIV | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/24/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $35.41 | General |
| Category: HIV | ||||||
| 09/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.47 | General |
| 09/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: HIV | ||||||
| 09/10/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $30.04 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.12 | General |
| 08/06/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/02/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/30/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $48.68 | General |
| Category: Infections and Infectious Diseases | ||||||
| 07/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $26.91 | General |
| Category: HIV | ||||||
| 07/16/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: HIV | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.34 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 441 | 809 | $145,575 | $69,551 |
| 2022 | 7 | 462 | 910 | $160,550 | $72,052 |
| 2021 | 7 | 455 | 890 | $141,072 | $76,640 |
| 2020 | 9 | 535 | 1,065 | $149,207 | $84,179 |
Total Patients
1,893
Total Services
3,674
Medicare Billing
$302,421
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 185 | 467 | $69,975 | $32,204 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 96 | $19,200 | $9,659 | 50.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 82 | $16,400 | $8,537 | 52.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 71 | 75 | $18,750 | $8,521 | 45.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 46 | $13,800 | $6,975 | 50.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $5,250 | $2,684 | 51.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 17 | 22 | $2,200 | $969.07 | 44.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 189 | 543 | $81,450 | $33,754 | 41.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 80 | 83 | $20,750 | $9,874 | 47.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 101 | $20,200 | $8,950 | 44.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 91 | $18,200 | $8,864 | 48.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 35 | $10,500 | $6,122 | 58.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $6,250 | $3,399 | 54.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 25 | 32 | $3,200 | $1,090 | 34.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 167 | 457 | $52,896 | $29,317 | 55.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 143 | $24,882 | $13,092 | 52.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 71 | 117 | $23,400 | $11,855 | 50.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 45 | 49 | $14,210 | $8,851 | 62.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 68 | 69 | $15,870 | $8,352 | 52.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $7,750 | $4,345 | 56.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 23 | 24 | $2,064 | $828.24 | 40.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 232 | 674 | $78,184 | $44,251 | 56.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 79 | 81 | $18,630 | $10,157 | 54.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 51 | 87 | $15,138 | $8,248 | 54.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 40 | 44 | $12,760 | $8,098 | 63.5% |
About Dr. Jane Pollner, MD
Dr. Jane Pollner, MD is a Infectious Disease healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265459812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jane Pollner, MD has received a total of $8,715 in payments from pharmaceutical and medical device companies, with $1,549 received in 2024. These payments were reported across 416 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($8,154).
As a Medicare-enrolled provider, Pollner has provided services to 1,893 Medicare beneficiaries, totaling 3,674 services with total Medicare billing of $302,421. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Fairfax, VA
- Active Since 07/17/2006
- Last Updated 07/12/2010
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1265459812
Products in Payments
- DOVATO (Drug) $1,259
- SYMTUZA (Drug) $461.06
- EGRIFTA (Drug) $421.30
- PIFELTRO (Drug) $375.73
- AVYCAZ (Drug) $313.52
- Mytesi (Drug) $300.17
- PREZCOBIX (Drug) $290.99
- TRIUMEQ (Drug) $268.47
- CABENUVA (Biological) $257.62
- APRETUDE (Biological) $219.10
- PREZISTA (Drug) $207.39
- Arikayce (Drug) $192.60
- Symtuza (Drug) $156.31
- ISENTRESS (Drug) $155.73
- DIFICID (Drug) $141.95
- Baxdela (Drug) $141.94
- Fetroja (Drug) $136.66
- Kimyrsa (Drug) $130.31
- ZERBAXA (Drug) $111.02
- Rezzayo (Drug) $93.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Fairfax
Dr. Stephen Weinroth, Md, MD
Infectious Disease — Payments: $156,236
Infectious Disease $156,236
Dr. Marsha Soni, Md, MD
Infectious Disease — Payments: $12,569
Infectious Disease $12,569
Trevor Uyemura
Infectious Disease — Payments: $7,348
Infectious Disease $7,348
Martin Ucanda, Md, MD
Infectious Disease — Payments: $3,579
Infectious Disease $3,579
Dr. Vijender Bajwa, M.d, M.D
Infectious Disease — Payments: $3,318
Infectious Disease $3,318
Gelareh Alavi, M.d, M.D
Infectious Disease — Payments: $902.11
Infectious Disease $902.11